Financial
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
HQ Denmark · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$24.6bn | +3.0% | US$4.7bn | US$3.6bn | Danaher group |
Products not yet catalogued.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
No adverse media (lawsuits, restructuring, misconduct or financial distress) involving Radiometer found in HSH's search of the last 24 months.
No data breaches, cyber incidents or regulator actions involving Radiometer found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Aug 2026: Radiometer began an FDA Class 2 correction of ABL90 FLEX/FLEX PLUS blood gas analysers (software 3.6 and lower) over potentially inaccurate results, updating instructions for use. In Mar 2025 a separate Class 2 recall addressed analysers freezing mid-measurement.
No contract disputes, terminations or notable NHS/UK contract events involving Radiometer found in HSH's search of the last 24 months.
No competitors linked yet.